A study to look at how safe different doses of atezolizumab were for patients – and how this medicine was processed through the body
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
Cancer Solid Tumors Tumor
Basic Details
Atezolizumab is a new medicine designed to work on the immune system, and this type of medicine is known as an immunotherapy. Patients with different types of cancers received different amounts of the study medicine to find out which dose of atezolizumab was safe, and which dose could be given to patients in future studies.
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
For the latest version of this information please go to www.forpatients.roche.com